Predictors for Retreatement of OAB After DC Mirabegron

NCT04550702 | Completed

• 1 other identifier: 202006091RIND
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.

Conditions

Recurrence of Overactive Bladder Syndrome

Keywords

overactive bladder syndrome; beta-3 agonist; retreatment

Outcome Measures

Primary Outcomes (1)

• Recurrent OAB

  Recurrent OAB with needs to retreatment

  January 2015 to July 2019

Study Arms (1)

Women received Mirabegron

Women with overactive bladder syndrome received Mirabegron

Drug: Mirabegron 25mg

Interventions

Mirabegron 25mg DRUG

Mirabegron 25 mg per day

Also known as: Betmiga

Women received Mirabegron

Eligibility Criteria

• Age: 20 Years - 85 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Women with overactive bladder syndrome who completed urodynamic study and bladder diary and received Mirabegron 25 mg per day

You may qualify if:

• Women with overactive bladder syndrome
• Women complete urodynamic study and bladder diary

You may not qualify if:

• Pregnant women
• Incomplete data
• Loss of follow-up
• Acute or chronic urinary tract infection

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

Related Publications (6)

• Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi: 10.1002/nau.20798.

  PMID: 19941278 RESULT

• Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr;103 Suppl 3:4-11. doi: 10.1111/j.1464-410X.2009.08371.x.

  PMID: 19302497 RESULT

• Hsiao SM, Lin HH. Medical treatment of female overactive bladder syndrome and treatment-related effects. J Formos Med Assoc. 2018 Oct;117(10):871-878. doi: 10.1016/j.jfma.2018.01.011. Epub 2018 Feb 15.

  PMID: 29398096 RESULT

• Hsiao SM, Su TC, Chen CH, Chang TC, Lin HH. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects. Maturitas. 2014 Sep;79(1):65-9. doi: 10.1016/j.maturitas.2014.06.001. Epub 2014 Jun 20.

  PMID: 25022469 RESULT

• Hsiao SM, Liao SC, Chen CH, Chang TC, Lin HH. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects. Maturitas. 2014 Dec;79(4):428-34. doi: 10.1016/j.maturitas.2014.08.009. Epub 2014 Sep 3.

  PMID: 25238744 RESULT

• Hsiao SM, Chang TC, Chen CH, Wu WY, Lin HH. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. Menopause. 2017 Jan;24(1):100-104. doi: 10.1097/GME.0000000000000730.

  PMID: 27648660 RESULT

MeSH Terms

Interventions

mirabegron

Study Officials

• Ho-Hsiung Lin, PhD

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2020
• First Posted: September 16, 2020
• Study Start: January 1, 2015
• Primary Completion: July 31, 2019
• Study Completion: July 31, 2019
• Last Updated: September 16, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)